267 related articles for article (PubMed ID: 24417755)
1. Cytokine levels of the aqueous humour in central serous chorioretinopathy.
Jung SH; Kim KA; Sohn SW; Yang SJ
Clin Exp Optom; 2014 May; 97(3):264-9. PubMed ID: 24417755
[TBL] [Abstract][Full Text] [Related]
2. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy.
Shin MC; Lim JW
Retina; 2011 Oct; 31(9):1937-43. PubMed ID: 21478806
[TBL] [Abstract][Full Text] [Related]
3. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.
Lim JW; Kim MU; Shin MC
Retina; 2010 Oct; 30(9):1465-71. PubMed ID: 20526231
[TBL] [Abstract][Full Text] [Related]
4. Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy.
Park J; Hwang SH; Nam DH; Lee DY
Korean J Ophthalmol; 2023 Dec; 37(6):453-461. PubMed ID: 37899289
[TBL] [Abstract][Full Text] [Related]
5. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
6. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
8. Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy.
Terao N; Koizumi H; Kojima K; Yamagishi T; Nagata K; Kitazawa K; Yamamoto Y; Yoshii K; Hiraga A; Toda M; Kinoshita S; Sotozono C; Hamuro J
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5924-5931. PubMed ID: 30551200
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
Roh MI; Kim HS; Song JH; Lim JB; Kwon OW
Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
[TBL] [Abstract][Full Text] [Related]
10. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.
Kim GA; Rim TH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Eye (Lond); 2015 Jun; 29(6):732-40; quiz 741. PubMed ID: 25952951
[TBL] [Abstract][Full Text] [Related]
14. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
Lee ST; Adelman RA
J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026
[TBL] [Abstract][Full Text] [Related]
15. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
[TBL] [Abstract][Full Text] [Related]
16. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab.
Ozdemir O; Erol MK
Cutan Ocul Toxicol; 2014 Jun; 33(2):122-6. PubMed ID: 23848591
[TBL] [Abstract][Full Text] [Related]
17. Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection.
Lim JW; Han JR
Clin Exp Ophthalmol; 2011 Aug; 39(6):537-44. PubMed ID: 21819507
[TBL] [Abstract][Full Text] [Related]
18. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.
Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S
Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
Lim JW; Kim MU
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
